Biotech

New federal defense contract bolsters Applied DNA

By GREGORY ZELLER // A new multiyear, seven-figure contract will expand Applied DNA Sciences’ relationship with the Department of Defense. The Stony Brook-based supply-chain, anti-counterfeiting, anti-theft and product-authentication specialist announced Tuesday that it’s won a two-year, roughly $1.5 million competitive-bid contract through the federal Defense Logistics Agency. The contract, which runs through May 2019, was granted via a Rapid Innovation Fund that provides the DLA with “innovative technologies that can be rapidly inserted into acquisition…


An SBU sweep in Bioscience Hub’s latest round

By GREGORY ZELLER // Five research projects targeting advanced medical-imaging applications, computer-based drug discoveries and a range of new pharmaceutical treatments will be backed by the Long Island Bioscience Hub. The Center for Biotechnology at Stony Brook University, on behalf of the LIBH, announced Tuesday the fourth funding round of the Hub’s technology-commercialization initiative. This time around, a total of $400,000 has been earmarked for two “feasibility” and three “proof of concept” awards, each backing biomedical…


Big investment, tiny particles and a giant leap for BNL

BY MICHAEL FAIRLIE // Brookhaven National Laboratory is stepping up its electromicroscopy game, in a big way. The fiscal year 2017 New York State budget includes $15 million for the Upton laboratory to purchase and install a cryo-electron microscope, which will work in tandem with the National Synchrotron Light Source II, the world’s brightest synchrotron light source. The Cryo-EM will be the backbone of BNL’s new Long Island Facility for Electromicroscopy, a national user facility…


Applied DNA goes ‘Beyond’ in cotton quest

By GREGORY ZELLER // Applied DNA Sciences is going to Bed Bath & Beyond, but not because it needs new towels. Instead, the Stony Brook-based provider of DNA-focused supply chain, anti-counterfeiting and anti-theft technologies, as well as product-genotyping and product-authentication solutions, is incorporating its “textile molecular tag” technology into the national retailer’s Wamsutta line – cotton products that claim to be made exclusively from pure Pima cotton grown in California. Now, thanks to Applied DNA’s…


With unique tech, Applied DNA gets into in vitro

By GREGORY ZELLER // A Stony Brook-based biotech has embarked on a five-year mission to safeguard in vitro diagnostics. In vitro studies, sometimes called “test tube experiments,” involve microorganisms, cells and other biological molecules outside their normal biological context. In the molecular biology era, such tests – performed not only in test tubes but in flasks, petri dishes and other laboratory vessels – have increased in both frequency and importance. Now, Applied DNA Sciences –…


In protein interactions, it’s the little things that count

Fair warning to the protein complexes behind some of planet Earth’s most nefarious diseases, which have hid from mainstream researchers through decades of molecular science: Stony Brook University is coming for you. An SBU-led research team has created an automated computer server that calculates complex computations for modeling protein interactions. If that sounds like thick science, it is: Aside from water, proteins are the most abundant substance in living cells, and modeling their interactions with cellular…


Financing set, cannabinoid-concussion study aims high

By GREGORY ZELLER // And now, onto the science. Canadian mining exploration company Kitrinor Metals Inc. and Scythian Biosciences Inc., a Calgary-based biotech owned by Great Neck investment banker Jonathan Gilbert, have announced a pair of deals that complete first-round financing for Scythian, which is exploring cannabinoid-based treatments for concussions. The new deals add on to the $13.08 million (Canadian) in brokered financing, led by Ontario-based Clarus Securities Inc., already raised by Scythian Biosciences, which…


At Applied DNA, they’re really getting into leather

By GREGORY ZELLER // A new international partnership backed by a host of well-known global brands will develop DNA-based security and product-authentication solutions for the leather industries. Stony Brook-based biotech Applied DNA Sciences this week announced a “research agreement” with BLC Leather Technology Centre, a UK-based R&D firm that delivers a range of services to leather suppliers, manufacturers and distributors in some 40 countries. Applied DNA President and CEO James Hayward introduced the program March 30 at…


Stock deal locks funds for Scythian marijuana study

By GREGORY ZELLER // A Canadian R&D firm with Long Island roots has locked up the first tranche of a strategic investment that will fund a major study involving concussions and medical marijuana. Scythian Biosciences Inc. and Canadian mining exploration company Kitrinor Metals Inc. on Tuesday announced a “brokered private placement” that gives 32.7 million common shares of Calgary-based Scythian, owned by Great Neck investment banker Jonathan Gilbert, to an investment team including lead agent…


Northwell, drug-maker ink bioelectronics partnership

By GREGORY ZELLER // Bioelectronic medicine has taken another forward leap, thanks to the Feinstein Institute for Medical Research’s latest professional alliance. The research-and-development arm of the Northwell Health system announced Thursday that it will apply its cutting-edge bioelectronics and cell-therapy technologies to cardiology and hypertension cases through a new “strategic partnership” with United Therapeutics Corp. Financial terms were not disclosed, but United Therapeutics will “fund Northwell’s efforts in four research-and-development tracks” while ushering new…


Rockefeller researcher nabs Feinstein’s molecular prize

Advanced molecular-genetics studies have earned a Rockefeller University researcher accolades from the Feinstein Institute for Medical Research, and a fat check. While Feinstein Institute scientists are often the ones collecting the research prizes, this time the institute is dishing it out, naming Jeffrey Ravetch – head of the Leonard Wagner Laboratory of Molecular Genetics and Immunology at The Rockefeller University in New York City – the recipient of the fifth-annual Ross Prize in Molecular Medicine….


Fighting forced labor, Applied DNA forms cotton club

By GREGORY ZELLER // So, where does your cotton come from? Applied DNA Sciences would like you to know. Adding to its portfolio of crimefighting products and services, the Stony Brook-based biotech has identified lead genetic markers unique to cotton cultivars – produced intentionally by genetic breeding – grown in Uzbekistan, where forced human labor is used to harvest the fluffy fiber. Now, the anti-counterfeiting and product-authentication specialist is “seeking out partners” in an effort…


Scythian, U of M concussion study hits the jack-pot

By GREGORY ZELLER // A Calgary-based R&D firm with strong Long Island ties has swung an eight-figure financing deal, lighting up a major study pitting cannabinoids against concussions. Scythian Biosciences Inc. – owned by owned by Great Neck investment banker Jonathan Gilbert, who partners in fitness-nutrition enterprise Decision Nutrition with his wife, Keren Gilbert, among other ventures – and the University of Miami stand ready with a planned five-year, $16 million study of cannabinoid-based methods…


GE brings good things to bioelectronics research

By GREGORY ZELLER // General Electric is giving the Feinstein Institute for Medical Research a bioelectronic jolt. The Feinstein Institute, R&D mecca of the Northwell Health system, announced a new “strategic alliance” Tuesday with GE Ventures, the multinational conglomerate’s New Jersey-based business-licensing and equity arm. While no financial terms were disclosed, Northwell Health did note an “investment” that will help the Feinstein Institute’s evolving Center for Bioelectronic Medicine “continue its work in discovering, developing and…


New patent, new partnership for soaring Traverse

By GREGORY ZELLER // When a new U.S. patent is your second-biggest announcement of the day, you’re probably in a good place. It’s all smiles (with healthy teeth, of course) lately at Stony Brook-based Traverse Biosciences, which on Tuesday announced a new patent and a material transfer agreement with what CEO Joseph Scaduto dubbed “a top-10 global animal-health company” – essentially, an agreement to privately test flagship formula TRB-N0224 against a host of animal illnesses. That’s…